Loading clinical trials...
Loading clinical trials...
Safety, Tolerability, and Adherence to Co-formulated Emtricitabine-rilpivirine-tenofovir Used as HIV Nonoccupational Post Exposure Prophylaxis in Men Who Have Sex With Men (EPEP)
Conditions
Interventions
Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg
Locations
4
Australia
Sydney Sexual Heatlh Centre
Sydney, New South Wales, Australia
St Vincents Hospital
Sydney, New South Wales, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Melbourne Sexual Health Centre
Melbourne, Victoria, Australia
Start Date
December 1, 2012
Primary Completion Date
July 1, 2014
Completion Date
July 1, 2014
Last Updated
January 12, 2015
Lead Sponsor
Andrew Carr
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions